arrow
M

Martin Hentemann

Bayer AG
H指数:14
被引数:1,146

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Discovery of FHD-286, a First-in-Class, Orally Bioavailable, Allosteric Dual Inhibitor of the Brahma Homologue (BRM) and Brahma-Related Gene 1 (BRG1) ATPase Activity for the Treatment of SWItch/Sucrose Non-Fermentable (SWI/SNF) Dependent Cancers

发现FHD-286,一种首创、口服生物利用的别构双抑制剂,可抑制Brahma同源物(BRM)和Brahma相关基因1(BRG1)的ATP酶活性,用于治疗SWItch/Sucrose Non-Fermentable(SWI/SNF)依赖性癌症。

2025-01-133
PRE
Identification of TNO155, an Allosteric SHP2 Inhibitor for the Treatment of Cancer
2020-09-10131
PREAI
Discovery and SAR of Novel 2,3-Dihydroimidazo[1,2-c]-quinazoline PI3K Inhibitors: Identification of Copanlisib (BAY 80-6946)

新型2,3-二氢咪唑并 [1,2-c]-喹唑啉PI3K抑制剂的发现和SAR: Copanlisib (BAY 80-6946) 的鉴定

2016-06-1698
OAAI
BAY 80-6946 Is a Highly Selective Intravenous PI3K Inhibitor with Potent p110α and p110δ Activities in Tumor Cell Lines and Xenograft Models

BAY 80-6946是一种高度选择性的静脉内PI3K抑制剂,在肿瘤细胞系和异种移植模型中具有有效的p110α 和p110δ 活性

2013-11-06237
OAAI
Discovery of Selective and Potent Inhibitors of Gram-Positive Bacterial Thymidylate Kinase (TMK)
2012-10-2439
PREAI
In Vivo Validation of Thymidylate Kinase (TMK) with a Rationally Designed, Selective Antibacterial Compound
2012-08-2838
PREAI